A prospective, multicenter, randomized, double-blind, controlled study of
ADCON-L Anti-Adhesion Barrier Gel (a medical device by Gliatech Inc, Cleveland,
OH) was conducted in 298 patients undergoing first-time lumbar
discectomy to evaluate the safety and effectiveness of
ADCON-L in preventing postoperative peridural
fibrosis and in improving patient clinical outcome. After lumbar
discectomy, patients were randomized to receive either
ADCON-L gel or nothing (control group) at the conclusion of the
surgical procedure. Six months after surgery, peridural
scar was evaluated by magnetic resonance imaging, and
postoperative pain and straight-leg-raise angle were assessed. No statistically significant differences between the
ADCON-L and control groups were observed in terms of adverse events or wound healing characteristics.
ADCON-L gel was shown to be safe and to significantly inhibit peridural
scar compared with the control group (P = 0.002). That peridural
scarring was reduced with
ADCON-L gel was further supported by direct visualization of
scar tissue at reoperation in both groups.
ADCON-L-treated patients had better clinical outcomes than did control patients. The incidence of activity-related
pain was significantly reduced (P = 0.013), straight-leg-raise examination scores were significantly improved (P = 0.024 on the operative side and P = 0.015 on the nonoperative side), and
ADCON-L reduced
low back pain when it was most severe (P = 0.047) and at the end of the day (P = 0.044).